Q1 2026 Treace Medical Concepts, Inc Earnings Call Transcript
Key Points
- Treace Medical Concepts Inc (TMCI) has expanded its portfolio with multiple new procedure innovations, positioning the company to address a broad spectrum of surgeon and patient preferences across all bunion classes.
- The company has reported sustained mid-single-digit case volume momentum, reinforcing confidence in its strategy to expand market penetration and improve top-line growth.
- Approximately 35% of the Lapiplasty surgeon user base has incorporated at least one of the three new bunion systems into their practice, indicating strong adoption of new products.
- Treace Medical Concepts Inc (TMCI) is on track to commercialize its next-generation Lapiplasty platform, Lapiplasty Lightning, which offers enhanced precision and control.
- The company has expanded its offerings with new SpeedPlate implants, sterile instruments, and its first biologics offerings, enabling the sales force to support surgeons' needs comprehensively.
- Treace Medical Concepts Inc (TMCI) reported a revenue decline of approximately 10% in Q1 2026, primarily due to a shift in revenue mix towards lower-priced, minimally invasive products.
- The company experienced a net loss of $18 million or $0.28 per share in the first quarter, compared to a net loss of $15.9 million or $0.25 per share in the first quarter of 2025.
- Adjusted EBITDA for the first quarter was a loss of $5.5 million, compared to a loss of $3.8 million in the first quarter of 2025.
- Revenue declines are expected to continue until the seasonally strongest fourth quarter, with full-year 2026 revenue projected to decline by 5% to 0% compared to 2025.
- The company faces ongoing macro pressures on procedure demand and portfolio mix shifts, which impacted performance in 2025 and continue to be present.
Good day, and thank you for standing by. Welcome to the Treace Medical Concepts first quarter 2026 earnings conference call.
(Operator Instructions) Please be advised that todayâs conference is being recorded. I would now like to hand the conference over to your speaker today, Philip Taylor. Please go ahead.
Good morning, everyone, and welcome to our first quarter 2026 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer, and Mark Hair, Chief Financial Officer. John and Mark will discuss our first quarter financial results in 2026 outlook.
We will then host a question-and-answer session following our prepared remarks. Our press release can be found in the investor relations section of our website at investors.treace.com. This call is being recorded and will be archived in the investor section of our website.
Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during todayâs call will be protected
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
